Cargando…
Timing of therapies for Down syndrome: the sooner, the better
Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alter...
Autores principales: | Stagni, Fiorenza, Giacomini, Andrea, Guidi, Sandra, Ciani, Elisabetta, Bartesaghi, Renata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594009/ https://www.ncbi.nlm.nih.gov/pubmed/26500515 http://dx.doi.org/10.3389/fnbeh.2015.00265 |
Ejemplares similares
-
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
por: Giacomini, Andrea, et al.
Publicado: (2015) -
Targeting APP/AICD in Down syndrome
por: Guidi, Sandra, et al.
Publicado: (2017) -
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2021) -
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives
por: Stagni, Fiorenza, et al.
Publicado: (2022) -
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2017)